Leading the Way in Life Science Technologies

GEN Exclusives

More »


More »
November 15, 2010 (Vol. 30, No. 20)

Epigenetic Modifications on Histones

Homogeneous Nonradioactive Assays to Monitor Methylation Process

  • The expression of the thousands of genes present in the human cell is regulated by dynamic changes in chromatin compaction throughout the different regions of the genome. The activity of chromatin-remodeling machineries, as well as changes in DNA-methylation patterns and histone post-translational modifications by specialized enzymes, are all biochemical strategies that cells employ to modulate gene expression.

    For instance, DNA methylation on CpG islands as well as methylation of histone H3 on specific lysine residues are events associated with chromatin condensation leading to transcriptional repression. Conversely, lysine acetylation of histones is generally related to open chromatin structures with higher rates of transcription.

    In this regard, there is a growing body of evidence that associates the activity of both histone methyltransferases (HMTs) and acetyltransferases (HATs) with different human pathologies, from malignancies to neuropathies. Thus, the development of molecular probes for these enzyme families could enable biologists to study in more depth the complex role of histone modifications in gene regulation, and provide a starting point to new drug discovery.

    A variety of radioactive-based assays have been reported in the literature for identifying compounds that modulate the activity of histone-modifying enzymes. Scintillation proximity assays (SPA) and FlashPlate® have been successfully developed to monitor the activity of HMTs by measuring the transfer of the methyl group from the radiolabeled co-factor, S-adenosyl-L-methionine (SAM), to the ε-amino residue of lysines on histone-derived peptidic substrates. However, as HMTs can perform either mono-, di-, or tri-methylation of lysines, measuring the incorporation of radioactive methyl groups does not provide information on the nature of the final reaction products.

    Mass spectroscopy (MS) is a non-radioactive alternative that has also been employed for studying the activity of HMTs and HATs. This technology allows the simultaneous characterization of the different methyl-lysine forms produced by certain HMTs, i.e., mono-, di-, or tri-methylated lysines. However, while recent technical advancements continue to improve MS throughput, plate-based detection assays remain the standard for speed and sensitivity in HTS applications.

  • Simplifying Hit Discovery

    Click Image To Enlarge +
    Figure 1. Lance Ultra SET7/9 methyltransferase assay optimization: All enzymatic reactions were performed in 10 µL (final assay volume: 20 µL). Detection has been carried out with an Eu-labeled antibody specific against the mono- and di-methylated forms of the Histone H3 peptide substrate (H3K4me1-2). (A) Enzymatic time course, at 200 nM biotin-H3 peptide substrate, and 100 µM SAM (saturating concentration). (B) SAM dose-response curve (5 nM SET7/9, 200 nM biotin-H3 peptide substrate). (C) Inhibitor dose-response curves (5 nM SET7/9, 200 nM biotin-H3 peptide substrate, 300 nM SAM).

    PerkinElmer’s Lance® Ultra and AlphaLISA® homogeneous assay platforms are two non-radioactive antibody-based technologies that have been demonstrated to be novel tools for the study and compound screening of a variety of enzymatic targets.

    Specific reagents for epigenetic research have now been developed for these platforms, to detect the in vitro enzymatic modification of histone H3-derived substrates (lysine acetylation or methylation). These microtiter plate assays consist of two main steps: the enzymatic reaction is performed first, followed by the detection of reaction products.

    During the enzymatic reaction step, appropriate concentrations of enzyme and biotinylated peptide substrate are incubated together in the presence or absence of test compounds. Following this, antimark europium-labeled antibody and ULight-labeled streptavidin (for Lance Ultra assay), or antimark AlphaLISA Acceptor beads and streptavidin-Donor beads (for AlphaLISA assays), are added to the reaction mix for product detection.

    The Lance Ultra and AlphaLISA reagents have been subjected to extensive optimization that includes a thorough analysis of the specificity of the antibody used to capture the modified residue. It is of note that for the AlphaLISA platform, covalent conjugation of antibodies to the Acceptor beads generally increased specificity and stability of the signal, when compared with an indirect capture of the antibody by Acceptor beads conjugated to an antispecies antibody. Moreover, the use of Acceptor bead-conjugated antibodies decreases background levels significantly, allowing for improved assay windows.

Related content